Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
1. A method of treating an ocular condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising a light chain variable domain sequence that is any one of SEQ ID NOs: 20-23,
wherein the light chain variable domain sequence comprises complementarity-determining region (CDR) sequences that are SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59, and
wherein the light chain variable domain sequence is contained within a light chain sequence that is any one of SEQ ID NOs: 34-37.
2. The method of claim 1 , wherein the ocular condition is diabetic retinopathy.
3. The method of claim 1 , wherein the ocular condition is neovascularization.
4. The method of claim 1 , wherein the ocular condition is vascular leak.
5. The method of claim 1 , wherein the ocular condition is increased intraocular pressure.
6. The method of claim 1 , wherein the ocular condition is ocular edema.
7. The method of claim 1 , wherein the ocular condition is diabetic macular edema.
8. The method of claim 1 , wherein the ocular condition is ocular hypertension.
9. The method of claim 1 , wherein the ocular condition is ocular inflammation.
10. The method of claim 1 , wherein the administering is to an eye of the subject.
11. The method of claim 1 , wherein the administering is intravitreal.
12. The method of claim 1 , wherein the administering is topical.
13. The method of claim 1 , wherein the subject is a human.
14. The method of claim 1 , wherein the therapeutically effective amount is from about 0.25 mg to about 200 mg.
15. The method of claim 1 , further comprising a heavy chain variable domain sequence that is any one of SEQ ID NOs: 9-12,
wherein the heavy chain variable domain sequence comprises CDR sequences that are SEQ ID NO: 54, SEQ ID NO: 55, and SEQ ID NO: 56, and
wherein the heavy chain variable domain sequence is contained within a heavy chain sequence that is any one of SEQ ID NOs: 29-32.
16. The method of claim 1 , wherein the antibody binds human protein tyrosine phosphatase-beta (HPTP-β).
17. The method of claim 1 , wherein the antibody binds an extracellular domain of HPTP-β.
18. The method of claim 1 , wherein the antibody binds a FN3 repeat of an extracellular domain of HPTP-β.
19. The method of claim 1 , wherein the antibody activates tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2 (Tie-2).
20. The method of claim 1 , wherein the antibody is humanized.